Mattsson, N; Scholl, M; Strandberg, O; Smith, R; Palmqvist, S; Insel, PS; Hgerstrom, D; ... Hansson, O; + view all Mattsson, N; Scholl, M; Strandberg, O; Smith, R; Palmqvist, S; Insel, PS; Hgerstrom, D; Ohlsson, T; Zetterberg, H; Jogi, J; Blennow, K; Hansson, O; - view fewer (2017) F-18-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. EMBO Molecular Medicine , 9 (9) pp. 1212-1223. 10.15252/emmm.201707809.

Preview

Text 1212.full.pdf - Published Version Download (1MB) | Preview

Abstract

To elucidate the relationship between cerebrospinal fluid (CSF) total‐tau (T‐tau) and phosphorylated tau (P‐tau) with the tau PET ligand 18F‐AV‐1451 in Alzheimer's disease (AD), we examined 30 cognitively healthy elderly (15 with preclinical AD), 14 prodromal AD, and 39 AD dementia patients. CSF T‐tau and P‐tau were highly correlated (R = 0.92, P < 0.001), but they were only moderately associated with retention of 18F‐AV‐1451, and mainly in demented AD patients. 18F‐AV‐1451, but not CSF T‐tau or P‐tau, was strongly associated with atrophy and cognitive impairment. CSF tau was increased in preclinical AD, despite normal 18F‐AV‐1451 retention. However, not all dementia AD patients exhibited increased CSF tau, even though 18F‐AV‐1451 retention was always increased at this disease stage. We conclude that CSF T‐tau and P‐tau mainly behave as biomarkers of “disease state”, since they appear to be increased in many cases of AD at all disease stages, already before the emergence of tau aggregates. In contrast, 18F‐AV‐1451 is a biomarker of “disease stage”, since it is increased in clinical stages of the disease, and is associated with brain atrophy and cognitive decline.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as XMLCSVJSON

Archive Staff Only

View Item